POSLUMA Becomes First and Only FDA-Approved PSMA-Targeted PET Imaging Agent
The US Food and Drug Administration (FDA) has approved Blue Earth Diagnostics’ prostate-specific membrane antigen (PSMA)-targeted positron emission tomography (PET) imaging agent, POSLUMA (flotufolastat F 18). The high-affinity radiohybrid is the first and only FDA-approved agent of its kind. It will be widely accessible for patients across the United States. ...
Advertisement
Advertisement

Latest News

Advertisement
Advertisement
Editorial Advisory Board

Expert Interviews

Knowledge Hubs

Curated clinical content based on conditions, therapies, and technologies

Prostate Cancer
Prostate Cancer

The Uromigos

Podcasts hosted by Professors Thomas Powles, MD, and Brian Rini, MD

Conference Coverage

Live meeting highlights

Zachary BessetteASCO 2023 | May 30, 2023
Tumor grade, sarcomatoid features may influence outcomes with adjuvant nivo/ipi in patients with RCC after nephrectomy.
Read More
Zachary BessetteASCO 2023 | May 30, 2023
EV plus pembrolizumab continues to demonstrate promising survival trends with durable responses in first-line la/mUC.
Zachary BessetteASCO 2023 | May 30, 2023
The prevalence, outcomes of patients with HRR mutations who initiated 1L mCRPC treatment with a novel hormonal therapy.
Zachary BessetteASCO 2023 | May 26, 2023
PSA nadir ≥0.1 ng/mL within 6 months of RT completion may be prognostic for long-term outcomes in patients receiving ...

Video Insights

Clinical discussions with experts in the field